| 1. |
- Angst, Jules, et al.
(författare)
-
Hypomania : a transcultural perspective
- 2010
-
Ingår i: World Psychiatry. - : Elsevier. - 1723-8617 .- 2051-5545. ; 9:1, s. 41-49
-
Tidskriftsartikel (refereegranskat)abstract
- This study examined the transcultural robustness of a screening instrument for hypomania, the Hypomania Checklist-32, first revised version (HCL-32 R1). It was carried out in 2606 patients from twelve countries in five geographic regions (Northern, Southern and Eastern Europe, South America and East Asia). In addition, GAMIAN Europe contributed data from its members. Exploratory and confirmatory factor analyses were used to examine the transregional stability of the measurement properties of the HCL-32 R1, including the influence of sex and age as covariates. Across cultures, a two-factor structure was confirmed: the first factor (F1) reflected the more positive aspects of hypomania (being more active, elated, self-confident, and cogni-tively enhanced); the second factor (F2) reflected the more negative aspects (being irritable, impulsive, careless, more substance use). The measurement properties of the HCL-32 R1 were largely invariant across cultures. Only few items showed transcultural differences in their relation to hypomania as measured by the test. F2 was higher among men and in more severe manic syndromes; F1 was highest in North and East Europe and lowest in South America. The scores decreased slightly with age. The frequency of the 32 items showed remarkable similarities across geographic areas, with two excep-tions: South Europeans had lower symptom frequencies in general and East Europeans higher rates of substance use. These findings support the interna-tional applicability of the HCL-32 R1 as a screening instrument for hypomania.
|
|
| 2. |
- Suppes, Trisha, et al.
(författare)
-
MAINTENANCE TREATMENT WITH QUETIAPINE WHEN COMBINED WITH EITHER LITHIUM OR DIVALPROEX IN BIPOLAR I DISORDER : ANALYSIS OF TWO LARGE RANDOMIZED, PLACEBO-CONTROLLED TRIALS
- 2013
-
Ingår i: Depression and anxiety (Print). - : Wiley-Blackwell. - 1091-4269 .- 1520-6394. ; 30:11, s. 1089-1098
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundTo determine the efficacy and safety of quetiapine combined with lithium or divalproex for preventing mood events in patients with bipolar I disorder. In this pooled analysis of two similar long-term studies (D1447C00126 [NCT00107731] and D1447C00127 [NCT00081380]), lithium and divalproex treatment groups were analyzed separately. MethodsPatients received open-label quetiapine (400-800 mg/d) plus lithium or divalproex to achieve 12 weeks of clinical stability before being randomized to double-blind combination treatment with quetiapine (400-800 mg/d) or placebo plus lithium or divalproex for up to 104 weeks. The primary endpoint was time to first mood event postrandomization following open stabilization. ResultsOf 3,414 patients in the stabilization phase, 1,326 were randomized. There were no differences in the risk of recurrence of mood, mania, or depression between quetiapine plus lithium or quetiapine plus divalproex. Among patients co-treated with placebo and lithium, the risk of recurrence of a mania event was significantly higher than among patients co-treated with placebo and divalproex. In patients with an index episode of mania, placebo plus lithium was associated with a significantly higher risk of recurrence of a mania event than placebo plus divalproex. Safety data were generally consistent with recognized safety profiles. ConclusionsIn patients with bipolar I disorder previously stabilized on quetiapine and lithium or divalproex, maintenance therapy with quetiapine significantly increased the time to recurrence of a mood event (mania or depression) versus placebo, regardless of whether it was combined with lithium or divalproex.
|
|
